目录产品 » TMEM106B hFc Chimera, Mouse
Manual
SDS
COAs

TMEM106B hFc Chimera, Mouse

TMEM106B is a well-recognised risk factor for FTD caused by GRN mutation. Elegant experiments have suggested that increased risk for FTD is due to elevated levels of TMEM106B (Nicholson et al, 2013; Gallagher et al, 2017). Therefore, recent work has explored the therapeutic potential of reducing TMEM106B levels, with initial results looking encouraging, as crossing a Grn-deficient mouse to a Tmem106b knockout showed a rescue in FTD-related behavioural defects and specific aspects of lysosome dysfunction (Klein et al, 2017).
￥3000
Z06379-100

产品简介
Species Mouse
Protein Construction
TMEM106B (Pro119-Gln275)_x000D_
Accession # Q80X71		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 44.8 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 65-68 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.
返回

图例
TMEM106B HFc Chimera, Mouse

The purity of TMEM106B hFc Chimera, Mouse is greater than 95% as determined by SEC-HPLC. »

TMEM106B HFc Chimera, Mouse

TMEM106B hFc Chimera, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

技术背景
Target Background TMEM106B is a well-recognised risk factor for FTD caused by GRN mutation. Elegant experiments have suggested that increased risk for FTD is due to elevated levels of TMEM106B (Nicholson et al, 2013; Gallagher et al, 2017). Therefore, recent work has explored the therapeutic potential of reducing TMEM106B levels, with initial results looking encouraging, as crossing a Grn-deficient mouse to a Tmem106b knockout showed a rescue in FTD-related behavioural defects and specific aspects of lysosome dysfunction (Klein et al, 2017).
Synonyms Transmembrane protein 106B;Tmem106b
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.